These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34477136)

  • 1. Longitudinal assessment of amyloid-beta deposition in initially amyloid-negative non-demented individuals with [11C]-PIB PET imaging.
    Hatashita S; Wakebe D
    Medicine (Baltimore); 2021 Sep; 100(35):e27055. PubMed ID: 34477136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.
    Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; Kennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ
    Neurology; 2009 Sep; 73(10):754-60. PubMed ID: 19587325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Kemppainen NM; Aalto S; Wilson IA; Någren K; Helin S; Brück A; Oikonen V; Kailajärvi M; Scheinin M; Viitanen M; Parkkola R; Rinne JO
    Neurology; 2007 May; 68(19):1603-6. PubMed ID: 17485647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
    Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
    Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
    Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfaction, Cognitive Impairment, and PET Biomarkers in Community-Dwelling Older Adults.
    Tian Q; Bilgel M; Moghekar AR; Ferrucci L; Resnick SM
    J Alzheimers Dis; 2022; 86(3):1275-1285. PubMed ID: 35180111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.
    Hatashita S; Yamasaki H
    J Alzheimers Dis; 2010; 21(3):995-1003. PubMed ID: 20693641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
    Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
    Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer's Disease.
    Hatashita S; Wakebe D; Kikuchi Y; Ichijo A
    Front Aging Neurosci; 2019; 11():251. PubMed ID: 31572167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold.
    Ismail R; Parbo P; Hansen KV; Schaldemose JL; Dalby RB; Tietze A; Kjeldsen PL; la Cour SH; Qvist P; Gottrup H; Eskildsen SF; Brooks DJ
    J Neuroimaging; 2019 Jul; 29(4):499-505. PubMed ID: 31074062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
    Diaz-Galvan P; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Jack CR; Min HP; Jain M; Miyagawa T; Forsberg LK; Fields JA; Savica R; Graff-Radford J; Jones DT; Botha H; St Louis EK; Knopman DS; Ramanan VK; Ross O; Graff-Radford N; Day GS; Dickson DW; Ferman TJ; Petersen RC; Lowe VJ; Boeve BF; Kantarci K
    Neurology; 2023 Jul; 101(2):e178-e188. PubMed ID: 37202168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.
    Raji CA; Becker JT; Tsopelas ND; Price JC; Mathis CA; Saxton JA; Lopresti BJ; Hoge JA; Ziolko SK; DeKosky ST; Klunk WE
    J Neurosci Methods; 2008 Jul; 172(2):277-82. PubMed ID: 18582948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
    Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF
    Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.